Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18121917 | 0.94 | CRHR1 (0.89) | CRHR1 | |
| SCHEMBL3737512 | 0.77 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL5600192 | 0.72 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL5847373 | 0.71 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL2401103 | 0.69 | CRHR1 (1.00) | CRHR1 | |
| Pexacerfont SCHEMBL2929753 | 0.67 | CRHR1 (1.00) | CRHR1 | |
| Pexacerfont SCHEMBL5235999 | 0.67 | CRHR1 (1.00) | CRHR1 | |
| Pexacerfont SCHEMBL5230356 | 0.67 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5815735 | 0.66 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL7220983 | 0.66 | CRHR1 (0.57) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170731-A1 | Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormallity | MALOPE COMPANY LIMITED (IE) | 2003-09-11 | — | — | US | claimed |
| EP-1305637-A2 | DIAGNOSIS AND TREATMENT OF NON-ULCER DYSPEPSIA BASED ON HYPOTHALAMIC-PITUITARY-ADRENAL AXIS ABNORMALITY | Malope Company Limited (IE) | 2003-05-02 | — | — | EP | claimed |
| WO-2002010756-A2 | DIAGNOSIS AND TREATMENT OF NON-ULCER DYSPEPSIA BASED ON HYPOTHALAMIC-PITUITARY-ADRENAL AXIS ABNORMALITY | MALOPE COMPANY LIMITED (IE) | 2002-02-07 | — | — | WO | claimed |
| WO-2026047334-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2026-03-05 | — | — | WO | disclosed |
| WO-2025036963-A1 | CREBBP/P300 HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CYTOPENIAS AND THEIR PATHOLOGICAL SEQUALAE | Technische Universität Dresden (DE) | 2025-02-20 | — | — | WO | disclosed |
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024175927-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175928-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-3096756-B1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES INC (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3568411-B1 | METHODS AND COMPOSITIONS FOR TREATING HPA HYPERACTIVITY | SANNA PIETRO P (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | HMNC VALUE GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | HMNC VALUE GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| EP-2094709-B1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1368094-B1 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A|-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20030170731-A1 | Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormallity | MALOPE COMPANY LIMITED (IE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | CRHR1, CRHR2, CRH | CRHR1 1/4885 |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | AVPR1B, CRHR1, AVPR1A | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.